Risks Associated with the Use of Psychotropics in Patients Diagnosed with Covid-19: An Integrative Review

Abstract

Background: In the context of the pandemic, negative implications for mental health increased significantly, increasing the existing associations of psychotropic drugs in this period of combating the new coronavirus. Objective: In this context, this study aimed to verify the health impact of Covid-19 infection in patients with mental disorders who make chronic and non-chronic use of psychotropic drugs. Design and setting: Integrative literature review conducted in Universidade Federal de Campina Grande. Method: The study is descriptive, retrospective, considered a systematic literature review, carried out through a search for original articles, in English, Spanish and Portuguese, available in full, published from December 2019 to July 2020 in the database of Science Direct. Searches will be carried out in August, September and October 2020, using the descriptors: 'Covid-19', 'Sertraline', 'Carbamazepine', 'Quetiapine', 'Pharmacological treatment', 'Psychiatry', 'Psychotic', and using the Boolean operators. Results: In this integrative review, a total of 146 articles were found, with the use of exclusion criteria, 21 articles were selected. The physician's choice of pharmacological treatment should be based on a careful and individualized assessment of each patient, considering the risks that associations between drugs frequently used to treat Covid-19 and those administered to control mental disorders. Conclusion:In this sense, with the evidence presented in this review, the article aims to demonstrate the important correlation between Covid-19 and psychiatric disorders, indicating paths for treatments and optimizing the time for recovery and support of those individuals who develop or make more explicit diseases of mental origin.